When is OBIO's latest earnings report released?
The most recent financial report for Orchestra biomed holdings, inc. (OBIO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OBIO's short-term business performance and financial health. For the latest updates on OBIO's earnings releases, visit this page regularly.
What is the operating profit of OBIO?
According to the latest financial report, Orchestra biomed holdings, inc. (OBIO) reported an Operating Profit of 6.75M with an Operating Margin of 21.85% this period, representing a growth of 140.5% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is OBIO's revenue growth?
In the latest financial report, Orchestra biomed holdings, inc. (OBIO) announced revenue of 30.92M, with a Year-Over-Year growth rate of 12,120.16%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does OBIO have?
As of the end of the reporting period, Orchestra biomed holdings, inc. (OBIO) had total debt of 32.44M, with a debt ratio of 0.28. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does OBIO have?
At the end of the period, Orchestra biomed holdings, inc. (OBIO) held Total Cash and Cash Equivalents of 34.69M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does OBIO go with three margins increasing?
In the latest report, Orchestra biomed holdings, inc. (OBIO) achieved the “three margins increasing” benchmark, with a gross margin of 99.8%%, operating margin of 21.85%%, and net margin of 19.4%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OBIO's profit trajectory and future growth potential.
Is OBIO's EPS continuing to grow?
According to the past four quarterly reports, Orchestra biomed holdings, inc. (OBIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.26. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of OBIO?
Orchestra biomed holdings, inc. (OBIO)'s Free Cash Flow (FCF) for the period is -2.3M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 83.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
